#United States #New Orleans #CAR-T therapy #Gene Editing #Factor Bioscience

Factor Bioscience Set to Present Innovations in Gene Editing at ASGCT 2025

Factor Bioscience Inc., a pioneering biotechnology firm situated in Cambridge, is gearing up to showcase its state-of-the-art innovations in gene editing and cell engineering at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting. This significant event will take place in New Orleans, Louisiana from May 13 to May 17, 2025. The company will offer insights into its cutting-edge research and developments, particularly focusing on allogeneic CAR-T cell therapy programs.

The ASGCT Annual Meeting stands as a major platform for scientists, researchers, and industry leaders to converge, share knowledge, and discuss the latest trends and breakthroughs in gene and cell therapy. Factor Bioscience aims to contribute substantially to these discussions with four enlightening presentations that will unveil preclinical data concerning their CAR-T cell therapies and other significant advancements in nucleic acid delivery systems and cell differentiation techniques.

Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor Bioscience, expressed enthusiasm about participating in this prestigious conference. He stated, "We are thrilled to present our latest findings, particularly regarding non-viral transgene insertion methodologies which are indispensable in the evolution of next-gen allogeneic CAR-T therapies and various cell/gene therapy applications." According to Dr. Angel, these advancements signify pivotal milestones towards the company’s overarching mission: enhancing health and life quality through innovative cell engineering technologies.

Dr. Kyle Garland, Director of Translational Science, also highlighted the company’s accomplishments over the past year. He noted that Factor has made significant progress by employing the advanced techniques established over the last fourteen years. This progress positions them well for sharing their latest developments with the community at ASGCT 2025.

The detailed presentations that Factor Bioscience will deliver are as follows:

• - UltraSlice Gene-Editing mRNA Enables Efficient Transgene Insertion into TRAC Locus in Primary Human T Cells (1757) presented by Ian Hay on May 15 from 5:30-7:00 PM, under the poster session revolving around Immunology, focused on CAR/TCR in T/NK and other immune cell types for Autoimmune and Infectious Diseases.
• - Incorporation of 5-methoxyuridine Enables Efficient Targeted Transgene Insertion in iPSCs and T Cells (1173) presented by Cassandra Ng on May 14 from 5:30-7:00 PM, in the poster session concerning Nonviral Delivery, emphasizing DNA/RNA drug development technologies.
• - A Novel Polyvalent Ionizable Lipid Library for Nebulized Delivery of mRNA to Lung Cells (682) presented by Joseph Pisano on May 13 from 6:00-7:30 PM, focusing on technological advancements in lipid nanoparticles for nonviral delivery.
• - Neural Induction of Gene-Edited mRNA-Reprogrammed iPSCs Yields Highly Proliferative Neural Stem and Progenitor Cells That Display Persistent Transgene Expression (1266) presented by Claire Aibel on May 14 from 5:30-7:00 PM, with an emphasis on cell therapies that incorporate or exclude ex-vivo genetic modification.

For additional details regarding the ASGCT Annual Meeting, interested parties can visit annualmeeting.asgct.org.

About Factor Bioscience

Established in 2011, Factor Bioscience specializes in utilizing a patented gene-editing platform to forge life-saving cell and gene therapies. As a private entity headquartered in Cambridge, Massachusetts, the company remains dedicated to transforming the field of biotechnology. For more information, visit www.factorbio.com.